Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline for prevention of weight regain in obesity
ACTRN12612000069853Phase 4Completed
- Sponsor
- Health Research Council of New Zealand
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Cabergoline with Placebo (2 arms). Primary endpoint: Prevention of weight regain after initial weight loss. Started Dec 2011; status: completed.
02
Drugs
cabergoline
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12612000069853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000069853.